WASHINGTON DC—Doctors taking the unusual step of combining two experimental drugs to treat cancers in patients who have mutated BRCA — the gene conferring susceptibility to breast, ovarian and some other solid tumours — found that patients responded through what appears to be a synergistic action. Dr Geoffrey Shapiro, Director of the Early Drug Development Center at the Dana-Farber Cancer Institute in Boston presented findings at the American Association for Cancer Research Annual Meeting on the combination of sapacitabine (a nucleoside analogue) and seleciclib (a cyclin-dependent kinase inhibitor). He discussed the clinical potential of this technique with Peter Goodwin.
You may also like...
Clear-cell renal cell cancer: first molecular prognostic marker also brings scope for drug targeting 27 Feb, 2014 Childhood Cancer Treatment: Model For Adult Therapy — ASCO President 10 Jun, 2012 Breast Cancer: Combined Risk Assessment Prompts Treatment De-Escalation 16 Apr, 2018 Ribociclib Aids First-Line Endocrine Therapy in Premenopausal Advanced Breast Cancer 18 Apr, 2018
- Previous story Treatment “holidays” to overcome resistance in advanced melanoma?
- Next story Breast cancer chemoprevention: meta-analysis shows SERMs are highly effective
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014